Stockscreener 앱 받기
16.06
1.90%
0.30
시간 외 거래:
16.06
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
NEA group (NASDAQ: GLUE) discloses 9.6% Monte Rosa ownership - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results, Misses Estimates By $0.10 EPS - MarketBeat
Guggenheim Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $30.00 - MarketBeat
Monte Rosa Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Monte Rosa Therapeutics (GLUE) Quarterly Loss Tests Bullish Profitability Narrative - simplywall.st
Monte Rosa (GLUE) Reports Wider Q4 Loss of $0.55/Share vs $0.34 Estimate, Revenue Misses - AlphaStreet
Monte Rosa Therapeutics Reports Positive Clinical Data and $345M Financing, Advancing Multiple Phase 2 Trials into 2029 - Minichart
Is Monte Rosa Therapeutics Inc stock a hidden gem2026 Earnings Surprises & Advanced Technical Signal Analysis - baoquankhu1.vn
Monte Rosa Therapeutics, Inc. (GLUE) Reports Wider Loss Q4 EPS Estimates by 63.4% - AlphaStreet
Monte Rosa’s QuEEN™ Discovery Engine: AI-Driven Molecular Glue Degraders Targeting Undruggable Proteins in Biotechnology 4145465158 - Minichart
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Monte Rosa Therapeutics: Fourth Quarter Financial Results Overview - Bitget
Monte Rosa Therapeutics, Inc. Announces Executive Changes - marketscreener.com
Monte Rosa Therapeutics (GLUE) 2025 Financials: Q4 Loss, Revenue MissNews and Statistics - IndexBox
Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans - MarketBeat
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Investing News Network
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Monte Rosa Therapeutics Swings to Net Loss in Q4, Collaboration Revenue Falls - marketscreener.com
Monte Rosa Therapeutics: Q4 Earnings Snapshot - kare11.com
Monte Rosa Therapeutics : Corporate Presentation – March 2026 - marketscreener.com
Monte Rosa Therapeutics (NASDAQ: GLUE) touts MGD pipeline and major Novartis, Roche deals - Stock Titan
Monte Rosa Therapeutics Q4 revenue drops, net loss widens on lower milestone payments - TradingView
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q4 Revenue $2.8M - marketscreener.com
Monte Rosa Therapeutics (GLUE) extends cash runway to 2029 after $345M raise - Stock Titan
Heart risk, prostate cancer: Monte Rosa data and $345M war chest - Stock Titan
Does Monte Rosa (GLUE)–J&J ERLEADA Supply Deal Reframe GLUE’s MYC Degrader Investment Story? - simplywall.st
GLUE SEC FilingsMonte Rosa Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Monte Rosa rises on J&J collaboration for cancer therapy trial (GLUE:NASDAQ) - Seeking Alpha
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer - Bitget
Advanced prostate cancer trial tests MRT-2359 with J&J’s ERLEADA - Stock Titan
GLUE Stock Price, Quote & Chart | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates - MSN
Monte Rosa Therapeutics (GLUE) Likely to Surpass Earnings Forecasts: Will the Share Price Rise? - Bitget
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Monte Rosa Therapeutics (GLUE) to Release Quarterly Earnings on Thursday - MarketBeat
Monte Rosa Therapeutics earnings on deck amid revenue decline - Investing.com
Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data Update And New Public Offering - Yahoo Finance
How Monte Rosa’s MRT-2359 Prostate Cancer Data and Funding Plans Could Shape GLUE’s Risk‑Reward Profile - Yahoo Finance
Is Monte Rosa Therapeutics Inc. stock attractive for income investors2026 Institutional Moves & Daily Growth Stock Tips - Naître et grandir
LifeSci Capital Initiates Coverage of Monte Rosa Therapeutics (GLUE) with Outperform Recommendation - MSN
Profit Review: Will Monte Rosa Therapeutics Inc benefit from AI trendsJuly 2025 Breakouts & High Accuracy Trade Alerts - baoquankhu1.vn
What is Monte Rosa Therapeutics Incs market position2025 Momentum Check & Community Shared Stock Ideas - baoquankhu1.vn
Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359 - MSN
Decliners Report: Is Monte Rosa Therapeutics Inc forming a bullish divergenceIPO Watch & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Dunn Edmund, principal accounting officer, sells Monte Rosa (GLUE) shares for $2496 - Investing.com Canada
Monte Rosa Therapeutics (GLUE) officer auto-sells shares to cover RSU tax - Stock Titan
Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares - MarketBeat
Monte Rosa (GLUE) CEO Warmuth sells 5,466 shares under 10b5-1 plan - Stock Titan
GLUE (NASDAQ: GLUE) Rule 144 filing lists RSU vest and recent insider sales - Stock Titan
GLUE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Significant Increase in Short Interest - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Edmund Dunn Sells 25,164 Shares - MarketBeat
Edmund Dunn of Monte Rosa (GLUE) exercises options, sells 25,700 shares - Stock Titan
Markus Warmuth (GLUE) files Form 144 showing proposed sales and RSU dates - Stock Titan
Affiliate sale: GLUE (NASDAQ: GLUE) 536 shares via option exercise - Stock Titan
Monte Rosa Therapeutics CEO unveils pipeline progress at TD Cowen Health Care Conference - Traders Union
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Positive MRT-2359 Clinical Data Update - simplywall.st
Proposed sale: GLUE (NASDAQ: GLUE) 25,164 shares from option exercise 02/27/2026 - Stock Titan
TD Cowen Sticks to Their Buy Rating for Monte Rosa Therapeutics (GLUE) - The Globe and Mail
1.20%
0.06%
자본화:
|
볼륨(24시간):